Black Black

Dr. Black Black

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMorten Asser Karsdal
Morten Asser Karsdal
TCThomas R. Cox
Thomas R. Cox
Amelia ParkerAmelia Parker
Amelia Parker
NWNicholas Willumsen
Nicholas Willumsen
JSJannie Marie Bülow Sand
Jannie Marie Bülow Sand
SRSylvie Ricard-Blum
Sylvie Ricard-Blum
The extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some of these chronic pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased tissue degradation, and some exhibit a combination of both, leading to severe tissue alterations. To develop effective therapies for diseases affecting the lung, liver, kidney, skin, intestine, musculoskeletal system, heart, and solid tumors, we need to modulate the ECM’s composition to restore its organization and function. Across diverse organ diseases, there are common denominators and distinguishing factors in this fibroinflammatory axis, which may be used to foster new insights into drug development across disease indications. The 2nd Extracellular Matrix Pharmacology Congress took place in Copenhagen, Denmark, from 17 to 19 June 2024 and was hosted by the International Society of Extracellular Matrix Pharmacology. The event was attended by 450 participants from 35 countries, among whom were prominent scientists who brought together state-of-the-art research on organ diseases and asked important questions to facilitate drug development. We highlight key aspects of the ECM in the liver, kidney, skin, intestine, musculoskeletal system, lungs, and solid tumors to advance our understanding of the ECM and its central targets in drug development. We also highlight key advances in the tools and technology that enable this drug development, thereby supporting the ECM.

11 October 2024 in Drug Discovery Today
Verified
Journal Article
Closed access
SCSimon Cruwys
Simon Cruwys
PHPeter Hein
Peter Hein
BHBob Humphries
Bob Humphries
BBBlack Black
Black Black

1 November 2009 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
KHKoc-Kan Ho
Koc-Kan Ho
JBJames R. Beasley
James R. Beasley
LBLaura Belanger
Laura Belanger
BBBlack Black
Black Black
JCJui-Hsiang Chan
Jui-Hsiang Chan
MWMaria Webb
Maria Webb

1 December 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
SCSimon Cruwys
Simon Cruwys
PHPeter Hein
Peter Hein
BHBob Humphries
Bob Humphries
BBBlack Black
Black Black